Latest news
-
Glenmark’s generic equivalent of FloVent HFA fluticasone propionate MDI gets final approval from FDA
According to Glenmark, the FDA has approved the company’s ANDA for a generic equivalent of GSK’s FloVent HFA fluticasone propionate MDI with competitive generic therapy (GGT) designation. FloVent HFA was initially approved in 2004, and… [Read more . . .]
-
Rein Therapeutics restarts Phase 2 trial of LTI-03 inhaled dry powder synthetic peptide in patients with IPF
Rein Therapeutics announced the that the first patient has been dosed in a Phase 2 study evaluating its LTI-03 caveolin-1 scaffolding domain peptide DPI in patients with idiopathic pulmonary fibrosis, with interim data expected later… [Read more . . .]
-
AtaiBeckley announces plans for Phase 3 development of BPL-003 intranasal mebufotenin
AtaiBeckley said that it completed an End‑of‑Phase 2 meeting with the FDA regarding BPL‑003 intranasal mebufotenin for the treatment of treatment‑resistant depression (TRD) and that the agency indicated that it supports the company’s plan for… [Read more . . .]
-
Esperion to acquire Corstasis Therapeutics and its Enbumyst bumetanide nasal spray
US biopharm Esperion will pay $75 million in cash up front and up to $180 million in milestone payments to acquire Corstasis Therapeutics and its Enbumyst bumetanide nasal spray, the companies said. The deal also… [Read more . . .]
-
Cullgen calls off merger with Pulmatrix
According to Pulmatrix, Cullgen has terminated the 2024 merger agreement between the companies. Pulmatrix said that it would In December 2025, Pulmatrix and Cullgen announced that Chinese authorities had still not approved the merger, and… [Read more . . .]
Other recent news
-
SpliSense’s SPL84 inhaled antisense oligonucleotide for CF gets early PRIME designation from the EMA
-
NOFLU consortium gets HaDEA funding for development of an intranasal vaccine based on Ethris technology
-
SoftOx gets approval for SIS-02 Phase 1 trial of SIS hypochlorous acid inhalation solution
-
Phase 3 PROSERA trial of Gossamer Bio’s seralutinib DPI in patients with PAH misses its primary endpoint
-
Iconovo signs letter of intent with Lonza for spray dried formulation of additional inhaled biologics
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland
